Bill > HB1767

This bill, effective January 1, 2027, mandates that health insurers, mutual benefit societies, and health maintenance organizations in Hawaii must provide coverage for at least one generic opioid antagonist, which is a drug like naloxone hydrochloride used to reverse opioid overdoses, and its delivery device, such as a nasal spray or auto-injector. These medications and devices must be placed on the lowest cost-sharing tier of the insurer's formulary (list of covered drugs), not be subject to annual or lifetime dollar limits, and comply with federal mental health parity laws, meaning they cannot have stricter financial requirements or treatment limitations than other medical conditions. Prior authorization, a process requiring approval before a prescription is filled, will not be required for generic opioid antagonists and their devices, though it may be for non-generic versions. A pharmacy benefit manager, which manages prescription drug benefits for health plans, is also defined within the bill.

Health and Social Services

https://www.capitol.hawaii.gov/session/measure_indiv.aspx?billtype=HB&billnumber=1767&year=2026